Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease

R N Cunliffe, F R A J Rose, J Keyte, L Abberley, W C Chan, Y R Mahida

Abstract

Background and aims—Intestinal epithelial cell derived antimicrobial peptides of the defensin family may play a major role in host defence against microorganisms. Our aims were to (i) isolate, characterise, and investigate the processing of human defensin 5 (HD-5) in normal Paneth cells and (ii) investigate expression of HD-5 in active inflammatory bowel disease (IBD).

Methods—Antiserum raised against chemically synthesised putative mature HD-5 was used for immunohistochemistry and purification of HD-5 from extracts of normal terminal ileal crypts.

Results—In normal and Crohn’s disease terminal ileum, HD-5 immunoreactivity was seen in Paneth cells and in some villous epithelial cells. Normal colonic mucosa did not express HD-5 but HD-5 immunoreactivity was seen in cells in the colonic crypt region of many IBD samples. N-terminal amino acid sequence analysis of HD-5 purified from normal terminal ileal Paneth cells consistently showed the predicted sequence of the precursor form of the peptide. Following stimulation of isolated intact normal terminal ileal crypts, a truncated form of HD-5, with the N-terminal sequence GEDNQLAIS, was detected in the supernatant.

Conclusions—(i) HD-5 is present only in the precursor form in normal terminal ileal Paneth cells and is processed to the mature form during and/or after secretion, (ii) some villous epithelial cells express HD-5, and (iii) HD-5 is expressed by metaplastic Paneth cells in the colon in IBD.

Keywords: inflammatory bowel disease; human defensin 5; Paneth cells

The gastrointestinal tract is constantly exposed to a large population of microorganisms and their products. This exposure may occur following ingestion of contaminated food or beverages but is especially prominent in the colon where a large population of bacteria is resident in the lumen. The total population of approximately $10^{13}$ bacteria consists of about 400 different species. The mechanisms by which the host intestinal mucosa interacts with such a microbial load remain to be characterised. Recent studies in animal models suggest that dysregulation or impairment of host responses to the resident microorganisms may lead to chronic inflammatory bowel disease (IBD).

Host-microbial interactions in the normal gastrointestinal tract may vary in different sites. In contrast with the normal colon (where the presence of the resident flora may be of benefit to the host), a significant bacterial population in the nutrient rich environment of the small intestinal lumen would be disadvantageous to the host. The number of bacteria resident in the small intestine falls markedly from $10^{13}$ to $10^{9}$ in the ileum to $10^{6}$ in the upper small bowel. In addition to gastric acid and motility, it is likely that mucosal factors are responsible for maintaining the relative sterility of the small intestine. Such mucosal factors may represent components of the adaptive and innate immunity, and in which epithelial cells play a major role. In recent years, epithelial cell mediated innate host defences in the form of antimicrobial peptides and proteins have generated considerable interest. While mature enterocytes are capable of expressing antimicrobial peptides and proteins, Paneth cells have been the main focus of interest in this field. In addition to the antimicrobial proteins lysozyme, and secretory phospholipase A, studies in mice have shown that Paneth cells express antimicrobial peptides of the α-defensin family, which have been designated cryptdins. Murine Paneth cells have been shown to express numerous isoforms of cryptdin. Mouse Paneth cells have been shown to express human defensins 5 and 6 (HD-5 and HD-6), have been shown to be expressed by Paneth cells in humans. While HD-5 has been localised to Paneth cells and a recombinant version of the peptide has been

Abbreviations used in this paper: IBD, inflammatory bowel disease; HD-5, HD-6, human defensins 5 and 6; RP-HPLC, reverse phase-high performance liquid chromatography; TFA, trifluoroacetic acid; PBS, phosphate buffered saline; ITF, intestinal trefoil factor; HBSS, Hank's balanced salt solution; LPS, lipopolysaccharide; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; PVDF, polyvinylidene difluoride; TTBS, Tris-Tween buffered saline; CFU, colony forming unit.

www.gutjnl.com
produced, the native peptide has yet to be fully characterised.

In this study, we have raised antisera against chemically synthesised HD-5 and demonstrated expression of HD-5 in Paneth cells and also some epithelial cells in the villous region of the small intestine. Expression of HD-5 was absent in the normal colonic mucosa but strong immunoreactivity was seen in some epithelial cells in sections of mucosa with active ulcerative colitis and Crohn’s colitis. Using the antisera, native HD-5 was isolated and purified from acid extracts of normal terminal ileal crypts by cation exchange chromatography and reverse phase-high performance liquid chromatography (RP-HPLC). N-terminal sequence analysis consistently showed that HD-5 is present only in its precursor form in normal terminal ileal Paneth cells. Our studies following stimulation of isolated crypts with lipopolysaccharide and carbamylcholine chloride suggest that processing of pro-HD-5 to the mature form occurs during and/or after its secretion by Paneth cells.

Materials and methods

CHEMICAL SYNTHESIS OF HD-5 AND PRODUCTION OF ANTI-HD-5 ANTISERA

The putative mature form of HD5 (amino acid residues 63–94; fig 1) was chemically synthesised by an automatic peptide synthesiser (Model 431A, Applied Biosystems, Foster City, California, USA) using Fmoc chemistry. It was purified by RP-HPLC using a 10 µmol C18 preparative column (Brownlee column, Applied Biosystems) with a solvent gradient of acetonitrile in 0.1% trifluoroacetic acid (TFA) from 3.5% to 21% over the first 10 minutes, then from 21% to 42% over the next 20 minutes, and from 42% to 70% over the final minute. The purified synthetic peptide was characterised by N-terminal amino acid sequence analysis and mass spectrometry and was subsequently used to raise antisera. For the primary immunisation, New Zealand White rabbits were injected (subcutaneously) with 330 µg of the synthetic peptide (in 500 µl of normal saline and 500 µl of complete Freund’s adjuvant). Two boosts were given at 30 day intervals in the same way, except that incomplete, rather than complete, Freund’s adjuvant was used. Blood was drawn prior to immunisation (preimmune sample) and 10 days after each boost and the separated serum was stored at −80°C in the presence of 0.02% sodium azide.

TISSUE SAMPLES

Fresh normal and IBD terminal ileal and colonic mucosal samples were obtained from intestinal operation specimens resected for carcinoma (the normal mucosal samples were obtained more than 5 cm from the tumour) or active IBD. Additional normal and active IBD mucosal tissue was obtained from the pathology archive at University Hospital, Nottingham.

IMMUNOHISTOCHEMISTRY

Five micron sections of formalin fixed paraffin embedded intestinal tissue samples (normal duodenum n=9, normal jejunum n=2, normal terminal ileum n=12, normal colon n=6, terminal ileal Crohn’s disease n=2, colonic (rectal or proximal colonic) Crohn’s disease n=8, ulcerative colitis (involving rectum or proximal colon) n=13) were dewaxed in xylene and rehydrated through graded alcohols. Antigen retrieval was achieved by incubation with Pronase (Sigma, St Louis, Missouri, USA) at 1 mg/ml for 20 minutes at room temperature. Immunoperoxidase staining was performed using a Vectastain Elite Universal ABC kit (Vector Laboratories, Burlingame, California, USA) according to the manufacturer’s instructions. In brief, sections were incubated with blocking serum at room temperature for 30 minutes and then incubated for one hour at room temperature with a 1:2000 dilution of rabbit anti-HD-5 antiserum in phosphate buffered saline (PBS). Rabbit pre-immune serum diluted 1:2000 in PBS was used as a negative control. Endogenous peroxidase activity was quenched by incubation in 0.3% H2O2 in methanol for 20 minutes. Bound antibodies were detected by incubation with a biotinylated antirabbit IgG, followed by an avidin-biotinylated horseradish peroxidase complex. Peroxidase activity was developed with diaminobenzidine tetrahydrochloride and the sections were counterstained with haematoxylin. Immunoperoxidase staining was similarly performed on selected sections using anti-lysozyme (1:100; NeoMarkers, Union City, California, USA) and anti-intestinal trefoil factor (ITF; 1:400) polyclonal antiserum diluted in PBS. In addition, to verify specificity of the immunostaining with the anti-HD-5 antiserum, immunoadsorption was performed by incubating synthetic HD-5 at a concentration of 20 µg/ml in diluted anti-HD-5 antiserum for three hours at room temperature. In subsequent studies on tissue sections, immunolabelling with immunoadsorbed anti-HD-5 antiserum was compared with untreated antiserum.

ISOLATION OF SMALL INTESTINAL CRYPTS

Fresh normal terminal ileal mucosal samples were obtained from operation specimens resected for caecal carcinoma and mucosal strips were dissected from the submucosa and weighed (generally 2–4 g total). Intact crypts and crypt epithelial cells were detached from the basement membrane using EDTA, as previously described. In brief, mucosal strips were incubated in 1 mM dithiothreitol (Sigma) for 15 minutes at room temperature. Epithelial cells were subsequently detached by three 30 minute incubations in 1 mM EDTA (Sigma) at 37°C with continuous gentle stirring. Between each incubation mucosal samples were washed with calcium and magnesium free Hanks balanced salt solution (HBSS; Gibco BRL, Gaithersburg, Maryland, USA). Crypt epithelial cells, largely in the form of intact crypt structures, were obtained after the second and third incubations in EDTA, leaving an intact lamina propria covered by basement membrane.
In some experiments investigating secretion of HD-5, isolated crypts were washed three times in HBSS supplemented with calcium (Gibco BRL) and incubated at 37°C with 5% CO₂ for one hour in RPMI (Gibco BRL) containing 10⁻⁵ M carbamylcholine chloride (carbachol; Sigma) or 10 µg/ml lipopolysaccharide (LPS; from Escherichia coli 055:B5; Sigma). Crypt culture supernatants were dialysed against distilled water for 18 hours with a 1 kDa cut off dialysis membrane (Spectra Por, Pierce and Warriner, Chester, UK) at 4°C in the presence of peptidase inhibitors (1 mM phenylmethylsulphonyl fluoride, 1 mg/ml pepstatin, and 1 mg/ml leupeptin; Sigma), lyophilised, and resuspended in 0.1% acetic acid for further analysis.

**PREPARATION OF CRYPT CELL EXTRACTS**

The isolated epithelial crypts obtained during the second and third EDTA incubation steps were pooled and washed three times in HBSS by centrifugation at 400 g for 10 minutes. They were resuspended in 10% acetic acid, subjected to one cycle of rapid freeze-thawing to bring about cell lysis, and stirred for 18 hours at 4°C in the presence of peptidase inhibitors (as above). Supernatants (containing cationic peptides) were clarified by centrifugation (at 400 g for 10 minutes), lyophilised, resuspended in 0.1% acetic acid, and stored at −80°C for further use.

**ISOLATION OF HD-5 FROM CRYPT CELL EXTRACTS AND CULTURE SUPERNATANTS**

Acid extracts of epithelial crypts isolated from terminal ileal mucosal samples of five different resection specimens were pooled, applied to a cation exchange column (SP Sepharose Fast Flow; Pharmacia Biotech, Uppsala, Sweden) and eluted using a 0–1 M NaCl gradient. Eluted fractions were dialysed against distilled water for 18 hours with a 1 kDa cut off dialysis membrane (Spectra Por, Pierce and Warriner, Chester, UK), lyophilised, and resuspended in 0.1% acetic acid. Positive fractions were further purified by RP-HPLC using a 2.1x30 mm C18 analytical column (Brownlee column; Applied Biosystems) with a linear gradient of acetonitrile in 0.1% TFA from 3.5% to 70% over 37 minutes. All major RP-HPLC peak fractions were analysed by AU-PAGE and western blot analyses. Selected fractions were also analysed by gel electrophoresis.

**PREPARATION OF CRYPT CELL EXTRACTS**

**GEL ELECTROPHORESIS**

Crypt cell extracts were analysed at various stages during the HD-5 purification procedure by AU-PAGE, as previously described. In brief, acid urea (6.25 M)-15% polyacrylamide minigels were prerun with 5% acetic acid for one hour at 150 V. Samples were electrophoresed with 5% acetic acid at 150 V until the methyl green dye front had reached the end of the gel, which was then stained with Coomassie blue. Tris–Tricine SDS-PAGE Ready Gels (Bio-Rad Laboratories, Hemel Hempstead, UK) were also used, according to the manufacturer’s instructions.

**IMMUNOBLOTTING**

The presence of immunoreactive HD-5 in crypt cell extracts, purified extract fractions, and crypt culture supernatants was determined by dot blot and western blot analyses using the anti-HD-5 antisera. Synthetic HD-5 and human neutrophil peptide-1 (human defensin 1; Bachem Feinchemikalien AG, Switzerland) were used as standards. For dot blot, 10 µl volumes of sample in 0.1% acetic acid were applied to PVDF membranes (Pro Blot membranes, Applied Biosystems) using a microfiltration apparatus attached to a water-vac system. For western blot analysis, peptides were electroblotted from AU-PAGE gels to PVDF membranes in 0.7% acetic acid/10% methanol at 180 mA for 10 minutes using a Transblot cell (Bio-Rad). Membranes were fixed in 0.05% glutaraldehyde in Tris-Tween buffered saline (TTBS) for one hour, blocked in 2.5% skimmed milk in TTBS for 30 minutes, and incubated with a 1:2000 dilution of the HD-5 antisera in 2.5% skimmed milk/TBSS for one hour at room temperature. Where necessary, a 1:2000 dilution of rabbit preimmune antisera was used as a negative control. Blots were washed three times in TTBS and bound antibodies were subsequently visualised using the Vectastain Elite ABC kit as described above.

**PROTEIN SEQUENCING AND MASS SPECTROMETRY**

**N-terminal amino acid sequencing of both synthetic HD-5 and that isolated and purified from crypt cells and culture supernatants was performed by Edman degradation chemistry using**

---

**Figure 1** Predicted amino acid sequence of human defensin 5 (HD-5), based on the cDNA. Single letter amino acid code for prepro HD-5 is shown. The N-terminus of mature HD-5 is speculative. Conserved cysteines, characteristic of the α-defensin family, are shown in bold and amino acid residue numbering is shown in parentheses.
an Applied Biosystems 473A automated sequence, as previously described.\textsuperscript{6} Electrospray mass spectrometry analysis of purified peptides was performed using a Micromass Platform machine (Micromass UK Ltd, Wythenshawe, UK) and for the sample containing HD-5 purified from isolated (but not stimulated/cultured) ileal crypts, the raw data were transformed using the MaxEnt 1 algorithm.

**ANTIMICROBIAL ASSAY**

Antimicrobial activity of HD-5 isolated and purified as described above was studied using a colony forming unit (CFU) assay. A phoP mutant (CS015) of *Salmonella typhimurium* (gift from Dr S Miller, Massachusetts General Hospital, Boston, Massachusetts, USA), which is sensitive to defensins,\textsuperscript{24} was used as the test organism. An overnight culture of bacteria in 3\% trypticase soy broth was subcultured at 1:100 and grown for three hours to mid logarithmic phase at 37°C. Bacterial density was estimated photometrically, based on the fact that an OD\textsubscript{620} of 0.2 is equal to 5×10\textsuperscript{7} CFU/ml, and a working dilution of approximately 10\textsuperscript{6} CFU/ml was prepared in 10 mM sodium phosphate buffer (pH 7.4)-1\% trypticase soy broth. A sample of 10 µl of a 200 µg/ml solution of isolated HD-5 in 0.1\% acetic acid was mixed with 90 µl of bacterial suspension; 10 µl of a 200 µg/ml solution of synthetic magainin (an antimicrobial peptide) in 0.1\% acetic acid and 10 µl of 0.1\% acetic acid alone were used as positive and negative controls, respectively. The initial number of CFU was determined by immediately diluting 10 µl of the assay mix 100, 10 000, and 100 000-fold with sodium phosphate buffer and keeping on ice until ready for plating. The remaining assay mix was incubated at 37°C for three hours and CFU determined again following dilution (as described above). Each diluted assay mix (50 µl) was plated in duplicate onto blood agar plates using an automated spiral plater and incubated overnight at 37°C. Bacterial colonies were counted using a plate reader, and the average number of CFU/ml calculated.

**Results**

**PRODUCTION OF SYNTHETIC HD-5**

N-terminal amino acid sequence analysis of the purified synthetic mature HD-5 obtained revealed the expected N-terminus (fig 1; first 10 N-terminal amino acid residues analysed). The purified synthetic peptide was homogeneous by RP-HPLC (not shown) and mass spectrometry revealed a mass of 3582 Da. This corresponds exactly with the expected mass of the fully oxidised putative mature form of HD-5 in which all cysteines have formed disulphide bonds. This

![Image](http://example.com)
suggests that the synthetic peptide had spontaneously oxidised during the purification process.

IMMUNOHISTOCHEMISTRY
The anti-HD-5 antisera showed strong immunoreactivity to Paneth cells in the normal small intestine (duodenum, jejunum, and terminal ileum), often with immunoreactive material in the crypt lumen, suggesting active granule secretion (fig 2A-C). In addition, in five of 12 normal terminal ileal and one of two jejunal mucosal samples studied (but none of the duodenal samples), occasional epithelial cells located in the villus region and towards the top of the crypts were noted to be immunoreactive for HD-5 in a fine granular pattern, often confined to the apical half of the cell (figs 3A; 4A, C, D). These cells were morphologically distinct from Paneth cells. Similar HD-5 containing villous epithelial cells were also noted in both of the terminal ileal Crohn’s disease samples studied. Specificity of HD-5 immunoreactivity for villous epithelial cells and Paneth cells was demonstrated by complete loss of immunoreactivity when the anti-HD-5 antiserum was preadsorbed with synthetic HD-5 (fig 3B). Studies using sequential sections showed that the HD-5 expressing villous epithelial cells express ITF (fig 4A, B) but not lysozyme (fig 4C, D, E, F). In the normal colon, no HD-5 immunoreactive cells were seen (fig 5A). However, scattered cells with strong HD-5 immunoreactivity were seen in four of eight colonic Crohn’s disease and eight of 13 ulcerative colitis mucosal samples (fig 5B, C). These HD-5 positive cells were often seen in the crypt region. Studies using sequential sections revealed that these cells were morphologically identical to Paneth cells on haematoxylin and eosin staining, and also that they contained lysozyme on immunoperoxidase staining (not shown).

PURIFICATION AND CHARACTERISATION OF NATIVE HD-5
Anti-HD-5 antiserum was used to facilitate the isolation and purification of HD-5 present in Paneth cells of the normal small intestine. Crypts were isolated from normal terminal ileal mucosal samples obtained from five different resection specimens, extracted with acetic acid, pooled, and applied to a cation exchange column. Fractions eluting between 0.4 M and 1.0 M NaCl were immunoreactive for HD-5 by dot blot analysis (fig 6). Immunoblot analyses after acid-urea PAGE showed that HD-5 in all of these eluted fractions demonstrated similar electrophoretic mobility. Fractions eluting between 0.8 M and 1.0 M NaCl demonstrated the presence of a single major component with a mass of 8103.76 Da (fig 7C). The expected mass of the precursor form of HD-5, deduced from the amino acid sequence (amino acids 20–94; fig 1), is 8103.83 Da. AU-PAGE (fig 8A) and Tris-tricine SDS-PAGE analyses of this single peak showed one discrete protein band and a doublet/broad band with slower migration. Protein bands on the AU-PAGE gel were transferred to a PVDF membrane and used for N-terminal amino acid sequence analyses (fig 8A). All three amino acid sequences obtained were similar and identical to the predicted N-terminal sequence of the precursor form of HD-5. This is shown by a 2 log increase in CFU after incubation of purified precursor HD-5 with the phoP mutant of S typhimurium, which is sensitive to defensins. This is shown by a 2 log increase in CFU after incubation of purified precursor HD-5 with the phoP mutant of S typhimurium (average CFU/ml at 0 hours, 1.2×10^8; after three hours, 2.0×10^9), and is similar to the result obtained using 0.1% acetic acid as a negative control (average CFU/ml at 0 hours, 1.1×10^7; after three hours, 1.5×10^8). In contrast, the antimicrobial peptide magainin,
which was used as a positive control, demonstrated potent antimicrobial activity (average CFU/ml at 0 hours, 0; after three hours, $1.0 \times 10^3$).

**HD-5 SECRETION BY ISOLATED PANETH CELLS**

As HD-5 is present in the Paneth cells in the precursor form only, studies were performed to determine whether it is processed during secretion from the cells. Secretion by Paneth cells in isolated and intact epithelial crypts was stimulated using bacterial LPS and carbamyl-choline chloride. Supernatant samples were subjected to AU-PAGE and Tris-tricine SDS-PAGE, followed by immunoblot analyses. In addition to a band corresponding to the precursor form of HD-5, an additional HD-5 immunoreactive band of lower molecular weight was also seen (fig 8B). Such a pattern was consistently seen in separate western blot analyses of supernatant samples of stimulated crypts isolated from five separate ileal resection specimens (that is, from five subjects). Culture supernatant of stimulated crypts isolated from one resection specimen was applied to RP-HPLC and N-terminal amino acid sequencing of the purified HD-5 immunoreactive fraction revealed an N-terminally truncated version of the precursor form of HD-5 (N-terminal sequence: GEDNQLAIS, amino acids 36–94; figs 1, 8B). Further studies in which HD-5 was purified (by RP-HPLC) from pooled culture supernatant samples of stimulated crypts obtained from four other resection specimens showed the same N-terminally truncated version of the precursor form of HD-5 (N-terminal sequence: GEDNQLAIS).

**Discussion**

We have chemically synthesised the predicted mature form of HD-5 based on the cDNA sequence and used it to raise antisera. The subsequent immunohistochemical studies on sections of normal small intestinal mucosa showed strong immunoreactivity in Paneth cells, which was abolished when the antisera was preadsorbed with synthetic HD-5 (in addition, no immunostaining was demonstrated when the preimmune antisera was used). The anti-HD-5 antibody was subsequently used to facilitate the isolation and purification of native HD-5 from acid extracts of epithelial crypts isolated from fresh terminal ileal mucosal samples. During these and other (unpublished) studies, we did not see cross reactivity of the anti-HD-5 antisera.
to any other entity. Therefore, these studies suggest that the antisera is specific for HD-5.

Our immunohistochemical studies showed that in addition to Paneth cells, some villous epithelial cells in a number of terminal ileal mucosal samples also expressed HD-5. Similar HD-5 immunoreactive villous epithelial cells were also seen in sections of terminal ileal Crohn’s disease. These cells appear morphologically distinct from Paneth cells and do not express lysozyme (a Paneth cell specific product) but express the goblet cell specific product ITF. The nature and identity of these cells is unclear but they may represent the previously reported and rare “intermediate cells” which contain Paneth cell-like granules and mucin but not lysozyme. The function of these cells is unknown but their expression of HD-5 suggests that they may have a role in protection of the small intestinal mucosa from microbial invasion.

No HD-5 positive cells were seen in sections of normal colonic mucosa. However, HD-5 immunoreactive cells were present in the crypt region of a large proportion of colonic samples with active ulcerative colitis or Crohn’s disease. Studies on sequential sections suggest that the HD-5 expressing cells in the crypt region are metaplastic Paneth cells, which also express lysozyme (Mason and Taylor, Geller and Thung, and our unpublished observations). We have also demonstrated expression of HD-5 mRNA in colonic epithelial cells of mucosal samples with IBD (unpublished observations). It is likely that induction of HD-5 expression in the colon with active IBD represents the host epithelial response to luminal bacteria and their products. Recently, we have also shown expression of polymorphonuclear defensins in the surface epithelial cells (but not metaplastic Paneth cells) in active IBD. In other recent studies, expression of HD-5 in the female genital tract has also been shown to be upregulated by inflammation. Moreover, expression of epithelial β-defensins may also be induced by inflammation or infection.

To determine the amino acid sequence of the native peptide stored in normal small intestinal Paneth cells, HD-5 was isolated and purified from acid extracts of isolated ileal crypts. Native HD-5 eluted over a wide gradient of NaCl but western blot analysis showed HD-5 immunoreactive bands of similar electrophoretic mobility in all the eluted fractions. RP-HPLC analysis of HD-5 purified from isolated (but not cultured/stimulated) ileal crypts demonstrated the presence of a single peak. Mass spectral analysis of this sample showed
that the major component was a peptide with a mass of 8103.76 (expected mass of the precursor form (amino acids 20–94) of HD-5 based on the amino acid sequence is 8103.83 Da).

N-terminal sequence analysis of this sample of purified HD-5 was found to be that of the predicted precursor form of the protein (amino acids 20–94, fig 1). These studies demonstrate that HD-5 is stored in the precursor form in normal terminal ileal Paneth cells. Interestingly, AU-PAGE and SDS-PAGE analyses of the same sample demonstrated the presence of more than one band but the same N-terminal amino acid sequence (that of the precursor form of HD-5, amino acids 20–94, fig 1) was present in all of them. The presence of more than one band with the same N-terminal amino acid sequence and a similar mass could be due to (i) unfolding and refolding of precursor form of HD-5 into different intramolecular disulphide linkages, (ii) variation in a single amino acid at the C-terminus, or (iii) may represent an artefact of AU-PAGE.

In a recent study, Porter et al also identified the precursor form of HD-5 in terminal ileal mucosal extracts but found several truncated forms of the precursor protein and not the sequence of the predicted precursor form of HD-5, as in our study. As we consistently found only the N-terminal sequence of the predicted precursor form of HD-5, it is possible that the truncations of this protein demonstrated by Porter et al occurred during the isolation procedure. Our isolated precursor form of HD-5 did not demonstrate antimicrobial activity. The lack of antimicrobial activity of pro-HD-5 would also explain our previous unsuccessful attempts at its isolation from terminal ileal mucosal extracts using a sensitive antimicrobial assay. It is of interest that only the mature forms of cryptdins have been isolated from murine small intestinal Paneth...
cells. Recently it has been shown that the tissue metalloproteinase matrilysin is responsible for the processing of cryptdin precursors to their active mature forms within the murine Paneth cell. Human myeloid defensins are also stored in cytoplasmic granules in the mature form. Thus it is likely that processing of HD-5 in human Paneth cells (which do not express matrilysin; unpublished observations) differs from the processing of cryptdins in murine Paneth cells and that of human neutrophil defensins. Compared with myeloid defensins of humans and other species, the N-termini of cryptdins are extended by 4–6 amino acid residues. The presence of only the precursor form of HD-5 in normal Paneth cells implies that processing to the mature form occurs during or after secretion into the lumen. To investigate this further, Paneth cells in isolated epithelial crypts were stimulated to secrete their granules using bacterial LPS and the cholinergic agonist carbachol. Western blot analyses following AU-PAGE and SDS-PAGE of supernatant samples consistently demonstrated the presence of a smaller form of HD-5, and following RP-HPLC purification and N-terminal sequencing this has been identified as an N-terminally truncated (by 16 amino acid residues; N-terminal sequence: GEDNQDLAIS) version of the precursor form of HD-5. In view of the lack of availability of adequate amounts, antimicrobial activity of this purified truncated form of HD-5 has not been determined. The truncated form of HD-5 identified in our studies (N-terminal sequence: GEDNQDLAIS) has also been found to be one of the predominant forms of HD-5 present in the urine of ileal neobladder, implying that this step in the processing of the precursor form of HD-5 does indeed occur in vivo.

Our results suggest that HD-5 is stored in ileal Paneth cells as the precursor form, and that its processing occurs during and/or after granule secretion. Further processing of the molecule may occur in the crypt lumen by endogenous proteases.

Dr Cunliffe was supported by Alimentary Pharmacology and Therapeutics Fellowship of the Digestive Disorders Foundation (UK). We thank Drs Gordon Kearney and Kirsten Hobby (of Micromass UK Ltd, Wythenshawe, Manchester) for assistance with the mass spectral analyses.


Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease

R N Cunliffe, F R A J Rose, J Keyte, L Abberley, W C Chan and Y R Mahida

Gut 2001 48: 176-185
doi: 10.1136/gut.48.2.176